The brain reacting to COVID-19: analysis of the cerebrospinal fluid proteome, RNA and inflammation
暂无分享,去创建一个
J. Kjems | E. Düzel | F. Heppner | C. Meisel | M. Ralser | K. Ruprecht | S. Vielhaber | H. Radbruch | M. Mülleder | J. Kühn | S. Jarius | L. Sander | M. Venø | F. Kurth | D. Reinhold | W. Stöcker | P. Stubbemann | P. Körtvélyessy | K. Guttek | A. Goihl | F. H. Perschel | B. Teegen | Yan Yan | C. Otto | S. Streit | V. Farztdinov | H. Sadlowski | Matthias Endres | Paula Stubbemann
[1] E. Keller,et al. Cerebrospinal fluid findings in COVID-19: a multicenter study of 150 lumbar punctures in 127 patients , 2022, Journal of neuroinflammation.
[2] D. Perl,et al. Mild respiratory SARS-CoV-2 infection can cause multi-lineage cellular dysregulation and myelin loss in the brain , 2022, bioRxiv.
[3] I. Cobos,et al. Dysregulation of brain and choroid plexus cell types in severe COVID-19 , 2021, Nature.
[4] J. Saez-Rodriguez,et al. Deep spatial profiling of human COVID-19 brains reveals neuroinflammation with distinct microanatomical microglia-T-cell interactions , 2021, Immunity.
[5] D. Kell,et al. Persistent clotting protein pathology in Long COVID/Post-Acute Sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin , 2021, Cardiovascular Diabetology.
[6] Christoph B. Messner,et al. Ultra-fast proteomics with Scanning SWATH , 2021, Nature Biotechnology.
[7] Kathleen M. Jagodnik,et al. Gene Set Knowledge Discovery with Enrichr , 2021, Current protocols.
[8] K. Melmed,et al. Cerebrospinal fluid in COVID-19: A systematic review of the literature , 2021, Journal of the Neurological Sciences.
[9] K. Blennow,et al. Biomarkers for central nervous system injury in cerebrospinal fluid are elevated in COVID‐19 and associated with neurological symptoms and disease severity , 2020, European journal of neurology.
[10] C. Conrad,et al. Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19 , 2020, Nature Neuroscience.
[11] S. Kremer,et al. Cerebrospinal fluid features in COVID-19 patients with neurologic manifestations: correlation with brain MRI findings in 58 patients , 2020, The Journal of infectious diseases.
[12] J. Claassen,et al. Cerebrospinal Analysis in Patients With COVID-19 , 2020, Open forum infectious diseases.
[13] M. Aepfelbacher,et al. Neuropathology of patients with COVID-19 in Germany: a post-mortem case series , 2020, The Lancet Neurology.
[14] K. Mertz,et al. Correlates of critical illness-related encephalopathy predominate postmortem COVID-19 neuropathology , 2020, Acta Neuropathologica.
[15] H. Kamel,et al. Effects of COVID-19 on the Nervous System , 2020, Cell.
[16] B. Schraven,et al. Serum and CSF cytokine levels mirror different neuroimmunological mechanisms in patients with LGI1 and Caspr2 encephalitis. , 2020, Cytokine.
[17] B. Hemmer,et al. Cerebrospinal fluid findings in COVID-19 patients with neurological symptoms , 2020, Journal of the Neurological Sciences.
[18] Maria Thom,et al. The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings , 2020, Brain : a journal of neurology.
[19] T. Ueland,et al. Increased interleukin-6 and macrophage chemoattractant protein-1 are associated with respiratory failure in COVID-19 , 2020, Scientific Reports.
[20] Christoph B. Messner,et al. Ultra-High-Throughput Clinical Proteomics Reveals Classifiers of COVID-19 Infection , 2020, Cell Systems.
[21] S. Kremer,et al. Neurologic Features in Severe SARS-CoV-2 Infection , 2020, The New England journal of medicine.
[22] Wenzhong Liu,et al. COVID-19:Attacks the 1-Beta Chain of Hemoglobin and Captures the Porphyrin to Inhibit Human Heme Metabolism , 2020 .
[23] Florian P Bayer,et al. Robust, reproducible and quantitative analysis of thousands of proteomes by micro-flow LC–MS/MS , 2020, Nature Communications.
[24] Alex A Henneman,et al. iq: an R package to estimate relative protein abundances from ion quantification in DIA-MS-based proteomics , 2020, Bioinform..
[25] Sujata,et al. A Prospective Study of Neurologic Disorders in Hospitalized COVID-19 Patients in New York City , 2020 .
[26] Christoph B. Messner,et al. DIA-NN: Neural networks and interference correction enable deep proteome coverage in high throughput , 2019, Nature Methods.
[27] The UniProt Consortium,et al. UniProt: a worldwide hub of protein knowledge , 2018, Nucleic Acids Res..
[28] H. Heinze,et al. Biomarkers of Neurodegeneration in Autoimmune-Mediated Encephalitis , 2018, Front. Neurol..
[29] Babykumari P. Chitramuthu,et al. Progranulin: a new avenue towards the understanding and treatment of neurodegenerative disease , 2017, Brain : a journal of neurology.
[30] Param Priya Singh,et al. Progranulin, lysosomal regulation and neurodegenerative disease , 2017, Nature Reviews Neuroscience.
[31] M. Nishihara,et al. Progranulin Protects Hippocampal Neurogenesis via Suppression of Neuroinflammatory Responses Under Acute Immune Stress , 2017, Molecular Neurobiology.
[32] N. Pochet,et al. Dissecting the role of non-coding RNAs in the accumulation of amyloid and tau neuropathologies in Alzheimer’s disease , 2016, bioRxiv.
[33] C. Blauwendraat,et al. Cerebrospinal Fluid Progranulin, but Not Serum Progranulin, Is Reduced in GRN-Negative Frontotemporal Dementia , 2016, Neurodegenerative Diseases.
[34] C. Blauwendraat,et al. Serum Levels of Progranulin Do Not Reflect Cerebrospinal Fluid Levels in Neurodegenerative Disease. , 2016, Current Alzheimer research.
[35] J. Dalmau,et al. The clinical spectrum of Caspr2 antibody–associated disease , 2016, Neurology.
[36] J. Josse,et al. missMDA: A Package for Handling Missing Values in Multivariate Data Analysis , 2016 .
[37] H. Heinze,et al. Progranulin levels in status epilepticus as a marker of neuronal recovery and neuroprotection , 2015, Epilepsy & Behavior.
[38] Matthew E. Ritchie,et al. limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.
[39] H. Heinze,et al. Progranulin and Amyloid-β Levels: Relationship to Neuropsychology in Frontotemporal and Alzheimer's Disease. , 2015, Journal of Alzheimer's disease : JAD.
[40] Marco Y. Hein,et al. Accurate Proteome-wide Label-free Quantification by Delayed Normalization and Maximal Peptide Ratio Extraction, Termed MaxLFQ * , 2014, Molecular & Cellular Proteomics.
[41] R. Petersen,et al. Progranulin protein levels are differently regulated in plasma and CSF , 2014, Neurology.
[42] R. Balice-Gordon,et al. Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study , 2014, The Lancet Neurology.
[43] P. Damme,et al. Cellular Effects of Progranulin in Health and Disease , 2011, Journal of Molecular Neuroscience.
[44] Terry M. Therneau,et al. Faster cyclic loess: normalizing RNA arrays via linear models , 2004, Bioinform..
[45] Terence P. Speed,et al. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias , 2003, Bioinform..
[46] Hilde van der Togt,et al. Publisher's Note , 2003, J. Netw. Comput. Appl..
[47] A. Bateman,et al. Cellular Localization of Gene Expression for Progranulin , 2000, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[48] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .